Laxi-CV 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg, Clavulanic Acid 125 mg, and Lactobacillus 60 million spores. Amoxycillin, a broad-spectrum penicillin antibiotic, acts by inhibiting bacterial cell wall synthesis, making it effective against a wide range of gram-positive and gram-negative bacteria. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Amoxycillin by preventing bacterial resistance mediated through beta-lactamase enzymes. The inclusion of Lactobacillus, a probiotic strain, helps restore and maintain normal intestinal flora during and after antibiotic therapy, reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances. Laxi-CV 625 is indicated for the treatment of various infections such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, and dental infections caused by susceptible organisms. The combination therapy ensures a broader spectrum of antibacterial activity and improved clinical outcomes. It is essential to use this medication as prescribed by a healthcare professional, considering potential allergies to penicillins and monitoring for adverse effects such as gastrointestinal discomfort or hypersensitivity reactions. This product should be stored in a cool, dry place and kept out of reach of children.